Cite
HARVARD Citation
Platzbecker, U. et al. (2018). Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet oncology. 19 (12), pp. 1668-1679. [Online].